Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Feb;4(1):13-32.
doi: 10.1177/1756287211431976.

Best practice in the treatment of nonmuscle invasive bladder cancer

Anastasios Anastasiadis, Theo M de Reijke

Best practice in the treatment of nonmuscle invasive bladder cancer

Anastasios Anastasiadis et al. Ther Adv Urol. 2012 Feb.

Abstract

Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75-85% of patients with bladder cancer present with a disease that is confined to the mucosa (stage Ta, carcinoma in situ) or submucosa (stage T1). These categories are grouped as nonmuscle invasive bladder cancer (NMIBC). Although the management of NMIBC tumours has significantly improved during the past few years, it remains difficult to predict the heterogeneous outcome of such tumours, especially if high-grade NMIBC is present. Transurethral resection is the initial treatment of choice for NMIBC. However, the high rates of recurrence and significant risk of progression in higher-grade tumours mandate additional therapy with intravesical agents. We discuss the role of various intravesical agents currently in use, including the immunomodulating agent bacillus Calmette-Guérin (BCG) and chemotherapeutic agents. We also discuss the current guidelines and the role of these therapeutic agents in the context of higher-grade Ta and T1 tumours. Beyond the epidemiology, this article focuses on the risk factors, classification and diagnosis, the prediction of recurrence and progression in NMIBC, and the treatments advocated for this invasive disease.

Keywords: carcinoma in situ; chemotherapy; immunotherapy; noninvasive bladder tumour; transurethral resection.

PubMed Disclaimer

Conflict of interest statement

All authors state that they have no conflict of interest.

References

    1. Althausen A.F., Prout G.R., Jr, D” Daly J.J. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 1976. November; 116(5): 575–580 - PubMed
    1. Augustine A., Hebert J.R., Kabat G.C., Wynder EL. Bladder cancer in relation to cigarette smoking. Cancer Res. 1988. August 1; 48(15): 4405–4408 - PubMed
    1. Aveyard P., Adab P., Cheng K.K., Wallace D.M., Hey K., Murphy M.F. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int. 2002. August; 90(3): 228–39 Review. - PubMed
    1. Barlow L., McKiernan J., Sawczuk I., Benson M. (2009) A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU Int 104: 1098–1102 - PubMed
    1. Bjerregaard B.K., Raaschou-Nielsen O., Sørensen M., Frederiksen K., Christensen J., Tjønneland A. Tobacco smoke and bladder cancer–in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2006. November 15; 119(10): 2412–6 - PubMed

LinkOut - more resources